S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
NASDAQ:LIFE

aTyr Pharma (LIFE) Stock Price, News & Analysis

$1.97
-0.03 (-1.27%)
(As of 12:14 PM ET)
Today's Range
$1.97
$2.05
50-Day Range
$1.42
$2.02
52-Week Range
$1.08
$2.70
Volume
218,195 shs
Average Volume
544,900 shs
Market Capitalization
$133.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.67

aTyr Pharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
1,083.3% Upside
$23.67 Price Target
Short Interest
Healthy
0.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of aTyr Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.97) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

622nd out of 939 stocks

Biological Products, Except Diagnostic Industry

105th out of 157 stocks

LIFE stock logo

About aTyr Pharma Stock (NASDAQ:LIFE)

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

LIFE Stock Price History

LIFE Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Recap: aTyr Pharma Q4 Earnings
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Q4 2023 aTyr Pharma Inc Earnings Call
Atyr Pharma: Q4 Earnings Snapshot
aTyr Pharma's Earnings Outlook
The 3 Best Penny Stocks to Buy in February 2024
See More Headlines
Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
65
Year Founded
2005

Price Target and Rating

Average Stock Price Target
$23.67
High Stock Price Target
$35.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+1,083.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-50,390,000.00
Pretax Margin
-14,276.77%

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
$1.54 per share

Miscellaneous

Free Float
65,623,000
Market Cap
$135.50 million
Optionable
Optionable
Beta
1.25

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Sanjay S. Shukla M.D. (Age 52)
    M.S., President, CEO & Director
    Comp: $795.48k
  • Ms. Jill M. BroadfootMs. Jill M. Broadfoot (Age 62)
    Chief Financial Officer
    Comp: $556.62k
  • Ms. Nancy E. Denyes Krueger (Age 56)
    General Counsel & Corporate Secretary
    Comp: $532.13k
  • Xiang-Lei Yang Ph.D.
    Founder
  • Ms. Ashlee Dunston
    Director of Investor Relations & Corporate Communications
  • Mr. Peter Villiger
    Vice President of Corporate Development
  • Ms. Danielle Campbell
    VP of Human Resource
  • Dr. Leslie Nangle Ph.D.
    Vice President of Research
  • Dr. Ying J. Buechler Ph.D.
    Executive Director of Biologics Development & Manufacturing
  • Dr. David J. King Ph.D. (Age 65)
    Scientific Consultant
    Comp: $327.31k

LIFE Stock Analysis - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LIFE shares.
View LIFE analyst ratings
or view top-rated stocks.

What is aTyr Pharma's stock price target for 2024?

4 equities research analysts have issued twelve-month price objectives for aTyr Pharma's shares. Their LIFE share price targets range from $16.00 to $35.00. On average, they expect the company's share price to reach $23.67 in the next twelve months. This suggests a possible upside of 1,083.3% from the stock's current price.
View analysts price targets for LIFE
or view top-rated stocks among Wall Street analysts.

How have LIFE shares performed in 2024?

aTyr Pharma's stock was trading at $1.41 at the beginning of the year. Since then, LIFE shares have increased by 41.8% and is now trading at $2.00.
View the best growth stocks for 2024 here
.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 289,300 shares, an increase of 167.4% from the February 29th total of 108,200 shares. Based on an average trading volume of 521,200 shares, the days-to-cover ratio is presently 0.6 days.
View aTyr Pharma's Short Interest
.

When is aTyr Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LIFE earnings forecast
.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) released its earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13.

When did aTyr Pharma's stock split?

aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

aTyr Pharma (LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.04%), Vanguard Group Inc. (4.04%), Stonepine Capital Management LLC (0.82%), Pale Fire Capital SE (0.50%), Goldman Sachs Group Inc. (0.25%) and Goldman Sachs Group Inc. (0.25%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends
.

How do I buy shares of aTyr Pharma?

Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIFE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners